Skip to main
AOD-9604 Compound

A research digest of AOD-9604 — the hGH C-terminal fragment 176-191, read from the published literature, antilipogenic action first, null human efficacy stated plainly.

Where each claim came from

AOD-9604 claims point to named papers.

A small number beside a claim matches one paper. A public link appears when one is available.

Each small number names one paper

Where did each claim come from? A small number beside the claim points to one paper. The matching source gives the paper's name. You can check it there.

The papers cover mice, rats, rabbits, and pigs. Some also cover people or cells in a dish. Each study page says who was tested. Animal results stay apart from human results.

Paper titles remain as the authors wrote them. The title helps you find the right study. A public link is shown when one is available. A formal title doesn't make an early finding more sure.

  1. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. ↗
  2. Bornstein J, Ng FM, Heng D, Wong KP. Metabolic actions of pituitary growth hormone. I. Inhibition of acetyl CoA carboxylase by human growth hormone and a carboxyl terminal part sequence acting through a second messenger. Acta Endocrinol (Copenh). 1983;103(4):479-486. ↗
  3. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993;30(5):971-978. ↗
  4. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. ↗
  5. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. ↗
  6. Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014;101:66-83. ↗
  7. More MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):64-77. ↗
  8. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. 1994;33(6):1029-1037. ↗
  9. AOD-9604 (Metabolic Pharmaceuticals). Curr Opin Investig Drugs. 2004;5(4):437-441. ↗
  10. Halford JC. Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006;7(4):312-318. ↗
  11. Adan RA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther. 2010;87(6):748-751. ↗
  12. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. ↗
  13. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526. ↗
  14. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432. ↗